CARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting
SHANGHAI, June 1, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the results of the pivotal Phase II clinical trial in China (CT041-ST-01, NCT04581473) investigating satricabtagene autoleucel ("satri-cel", CT041) (a Claudin18.2-specific autologous CAR T-cell product candidate) in patients with Claudin18.2-positive, advanced gastric/gastroesophageal junction cancer refractory to at least two prior lines of treatment, have been published in The Lancet and were orally presented at the 2025 ASCO Annual Meeting. Further details have been posted on the corporate website https://www.carsgen.com.
The article in The Lancet was titled "Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial". Full article available at: https://doi.org/10.1016/S0140-6736(25)00860-8.
The oral presentation at the 2025 ASCO Annual Meeting (Abstract 4003) was titled "Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician's choice (TPC) for previously treated advanced gastric or gastroesophageal junction cancer (G/GEJC): Primary results from a randomized, open-label, phase II trial (CT041-ST-01)".
Professor Lin Shen from Beijing Cancer Hospital, the principal investigator of this study, said, "The CT041-ST-01 trial represents the world's first randomized controlled clinical study of CAR-T cell therapy for solid tumors. In patients with heavily pretreated, advanced gastric/gastroesophageal junction cancer who have extremely limited treatment options and poor prognosis, satri-cel has demonstrated breakthrough efficacy with significant clinical benefits, including much improved progression-free survival (PFS), overall survival (OS), and tumor response rates. This brings new hope to patients with otherwise medically untreatable conditions. We are further exploring satri-cel's potential in adjuvant settings and as first-line sequential therapies, aiming to intervene earlier in the disease course, extend patients' survival, and ultimately pursue potential cures."
Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics, said, "We are honored that the CT041-ST-01 study results were published in The Lancet—a premier, global medical journal—and presented at the 2025 ASCO Annual Meeting. The positive result of this randomized controlled trial marks a major milestone in solid tumor CAR-T therapy. These achievements are a testament to the whole research team's years of dedication, and we extend our deepest gratitude to patients and their families for their trust and participation. This year, satri-cel has been granted Breakthrough Therapy Designation and Priority Review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the treatment of Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) in patients who have failed at least two prior lines of therapy. We plan to submit a New Drug Application (NDA) for satri-cel to the NMPA this month and anticipate its approval as the world's first commercially available CAR-T product for solid tumors, bringing benefits to patients."
About Satri-cel
Satri-cel is an autologous CAR T-cell product candidate against the protein Claudin18.2 that has the potential to be the first-in-class globally. Satri-cel targets the treatment of Claudin18.2-positive solid tumors with a primary focus on G/GEJA and pancreatic cancer (PC). Initiated trials include investigator-initiated trials (CT041-CG4006, NCT03874897), a confirmatory Phase II clinical trial for advanced G/GEJA in China (CT041-ST-01, NCT04581473), a Phase Ib clinical trial for PC adjuvant therapy in China (CT041-ST-05, NCT05911217), an investigator-initiated trial for satri-cel be used as consolidation treatment following adjuvant therapy in patients with resected G/GEJA (CT041-CG4010, NCT06857786), and a Phase 1b/2 clinical trial for advanced gastric or pancreatic adenocarcinoma in North America (CT041-ST-02, NCT04404595).
Satri-cel has been granted Priority Review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy in May 2025. Satri-cel has been granted Breakthrough Therapy Designation by the CDE of China's NMPA for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy in March 2025. Satri-cel was granted Regenerative Medicine Advanced Therapy designation by U.S. FDA for the treatment of advanced G/GEJA with Claudin18.2-positive tumors in January 2022. Satri-cel received Orphan Drug designation from the U.S. FDA in September 2020 for the treatment of G/GEJA.
About CARsgen Therapeutics Holdings Limited
CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen's mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable.
Forward-looking Statements
All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group's current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group's control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading "Principal Risks and Uncertainties" in our most recent annual report and interim report and other announcements and reports made available on our corporate website, https://www.carsgen.com. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release.
Contact CARsgen
For more information, please visit https://www.carsgen.com/
View original content to download multimedia:https://www.prnewswire.com/news-releases/carsgen-presents-research-results-on-satri-cel-in-the-lancet-and-at-the-2025-asco-annual-meeting-302470028.html
SOURCE CARsgen Therapeutics
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
AmplifyeP24 Can Double Protein Absorption with One Daily Capsule
A Breakthrough Enzyme P24 Enhances Protein Bioavailability, Transforming Nutrition LOS ANGELES, June 3, 2025 /PRNewswire/ -- Amplifye, a biotechnology company specializing in enhancing protein nutrition through the development of proprietary enzymes, today announces the launch of its first consumer product, amplifyeP24. Without changing the amount of food you consume, amplifyeP24 can double protein absorption by breaking down proteins in the stomach into bioavailable peptides and free essential amino acids. amplifyeP24 is a single capsule taken once a day with your largest meal, that acts on the protein in the food you're already consuming. It works on any protein source, whether meat, plant, or supplement-derived. By doubling protein bioavailability, amplifyeP24 supports benefits such as deeper sleep, enhanced muscle recovery, digestive comfort, improved gut health, and sustained energy. Designed for diverse populations—from athletes pursuing peak performance to individuals with digestive challenges, or women in perimenopause trying to increase their protein consumption—amplifyeP24 bridges cutting-edge science with accessible health solutions. "Protein is one of the most essential nutrients we consume, yet much of it goes unused by the body," said John Melo, Chief Executive Officer, amplifye. "amplifyeP24 unlocks the full potential of the protein you already consume, doubling absorption for measurable improvements in performance, recovery, and wellness. Backed by extensive research, third-party lab testing, and rigorous scientific development, this breakthrough in nutrition delivers noticeable results quickly." Amplifye's proprietary enzyme, P24, leverages breakthrough science to enhance protein bioavailability. The company's precision enzyme platform optimizes human nutrition and transforms underutilized protein sources, creating new possibilities for sustainability across food, animal feed, aquaculture, and human health and wellness markets. "We didn't just develop a product—we discovered a completely new enzyme with extraordinary properties," said Courtney McHugh, co-founder and Chief Commercial Officer, amplifye. "The enzyme is built on years of research in enzymology and was inspired by foundational principles recognized with the Nobel Prize in 2024. This discovery allows us to solve a long-standing protein digestion and bioavailability challenge." Amplifye closed an $18.5M Series A funding round to accelerate the development and commercialization of its precision enzyme platform. The round was led by Magdalena, a global leader in sugar cane processing, with participation from UC Investments and Astanor Ventures. With the launch of amplifyeP24, Amplifye is poised to lead the charge in transforming the world's approach to protein nutrition. The company plans to expand its portfolio of enzyme-based solutions, continuing to leverage its proprietary platform to address diverse nutritional needs and drive innovation in health and sustainability. amplifyeP24 is now available for purchase at About AmplifyeOur mission is to amplify the nutritional impact of food while contributing to a more sustainable future. Amplifye is a pioneering biotechnology company that applies computational enzyme discovery and the power of precision fermentation. Coupled with AI, we develop and scale novel, clinically proven digestive enzymes that elevate the nutritional value of what we already eat. Amplifye combines scientific, nutrition, and engineering expertise, with a deep understanding of consumer needs, to make protein healthier for all, with no compromise. For more information. Please visit: Media Contacts:amplifye@ View original content to download multimedia: SOURCE Amplifye
Yahoo
30 minutes ago
- Yahoo
Noteworthy New Book "Cybersecurity Checklist for Business Owners" is Free Today on Amazon
Essential Battle Plan for Business Owners, Managers, and Stakeholders CHICAGO, June 3, 2025 /PRNewswire/ -- Cybersecurity expert William Clements is excited to share his new release, the Cybersecurity Checklist for Business Owners. This checklist tackles the soul-crushing risks that small businesses worldwide face from cybercrime. Although attacks on large organizations make the news, small businesses are criminals' favorite targets. For over 25 years, Mr. Clements has worked as a business consultant. He has advised hundreds of clients on information technology and cybersecurity. He knows the risks well from his experience. The book is currently free and available for download on Amazon today (until 6/7/2025). Get your copy here. Cybersecurity Checklist has reached #1 New Release on Amazon in both the Production & Operations and Information Management categories. The average rating is 5 stars. "When all stakeholders are well-informed, we will have a more secure world," said author Mr. Clements. Here's what some early readers have said: "This book was eye-opening, sobering, and surprisingly accessible. As a small business owner with no IT background, I was shocked (and troubled) by how many cyber risks I had never considered. More importantly, the practical steps gave me a clear path forward, combined with an appropriately strong sense of urgency to invest in cyber security today and into the future. As small business owners, we tell ourselves it won't happen to us; but the truth is, because we're small business owners, we can't afford for it to happen to us! A must-read for every business owner." -Patrick D "A must-read for any business leader. This book cuts through the noise with real-world examples, a practical checklist, and a clear action plan. It helped me uncover critical cybersecurity gaps; even after significant investment. More than a read; it's a guide to action." -Michael C About the Author: William Clements has managed cybersecurity and information technology for small and mid-sized businesses over the past 25 years. He has worked with hundreds of businesses in dozens of industries. He holds several cybersecurity industry certifications, such as CISSP, CCSP, and CISM. He founded the Chicago Technology Group, which keeps entrepreneurial businesses protected from cyber threats. View original content to download multimedia: SOURCE William Clements
Yahoo
32 minutes ago
- Yahoo
Barchart Launches Next Generation of cmdtyView for Excel, Unlocking Real-Time Market Data Across All Platforms
CHICAGO, June 3, 2025 /PRNewswire/ -- Barchart, a leading provider of market data, software and technology services to the commodity, media and financial sectors, has announced the release of its next-generation cmdtyView for Excel Add-In, bringing a modern, cross-platform solution to commodity traders, analysts and risk managers who depend on real-time data and custom analytics. Barchart's upgraded Microsoft® Excel® add-in is a powerful solution that allows users to stream live market data, physical commodity prices and global fundamental data directly into Excel on Windows, Mac and the web. It is a major upgrade from Barchart's legacy RTD-based tool with modern Microsoft Office 365 integration, custom functions and easy deployment that makes advanced analysis in Excel faster and more accessible. "Our new Excel add-in is a game changer for commodity professionals who demand power, flexibility and accessibility," said Chris Harrison, CPO at Barchart. "Whether you're at your desk or working remotely, this next-gen solution enables you to monitor real-time market movements and build complex models without being tied to one device or operating system," added Harrison. What's new in cmdtyView for Excel: True Cross-Platform Access: The new cmdtyView for Excel runs seamlessly on Windows, macOS and Excel for the Web, giving you full flexibility to stream real-time market data from any device, anywhere. Modern Technology Framework: Built on Microsoft's latest Office add-in APIs, the new solution delivers faster performance for large datasets, high-frequency data support, cloud-based deployment through the Office App Store and advanced custom functions that replace outdated RTD formulas. Portable and User-Centric: Your workspace now follows you. By tying the add-in to your Microsoft login, your access and settings stay consistent across all devices no matter where you are working. Smarter, Smoother User Experience: Discover data faster with an improved symbol browser, take advantage of tighter integration with Excel's built-in tools and benefit from seamless compatibility with other Office 365 services for a more intuitive and productive workflow. "This next-generation release reflects Barchart's ongoing commitment to creating solutions that not only meet today's needs but also anticipate where the industry is going. We're making Excel smarter, faster and more accessible for the global commodity community," added Harrison. To try out Barchart's next-generation cmdtyView for Excel or learn more, please click here. About BarchartBarchart is a leading provider of market data and services to the global financial, media, and commodity industries. Our diversified client base trusts Barchart's innovative Solutions across data, software, and technology to power their operation from front to back office, while our Media brands enable financial and commodity professionals to make decisions through web content, news, and publications. For more information, please visit Microsoft and Excel are trademarks of the Microsoft group of companies. View original content to download multimedia: SOURCE Barchart
